Opinion|Videos|April 11, 2025
Advancing Early Detection: Autoimmune Screening in Type 1 Diabetes
A panelist discusses how autoimmune screening through detection of diabetes-specific autoantibodies serves as a critical tool for identifying pre-symptomatic type 1 diabetes (T1D), enabling earlier intervention before significant beta cell loss occurs and potentially changing the disease trajectory through timely management strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role does autoimmune screening play in identifying and diagnosing patients with T1D earlier?
- In what patients do you recommend screening for autoantibodies?
- Do you think autoimmune screening initiatives will gain momentum in the next few years?
- How can health care systems and payers improve early screening and diagnosis to better preserve beta cell function?
Advertisement
Related to this article
Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.
In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.
Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.
In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.
CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.
Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.
States have to turn that information into medical frailty determinations that are clinically credible, consistent, and workable across large Medicaid populations.
A meta-analysis found steatotic liver disease in 75% of patients with sleep-disordered breathing and that CPAP lowered liver enzymes but not liver fat.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
New lean MASH mouse model could guide more targeted liver disease treatment in humans
2
FAQ: State PBM reform in 2026—What's new since spring
3
When the referral isn't the finish line: Making SDOH programs actually close care gaps
4
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
5